Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Operating Income (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Operating Income for 2 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • Quarterly Operating Income fell 9.65% to -$4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$175980.0 for FY2025, 95.48% up from the prior year.
  • Operating Income for Q4 2025 was -$4.1 million at Neuphoria Therapeutics, up from -$5.7 million in the prior quarter.
  • The five-year high for Operating Income was $12.0 million in Q1 2025, with the low at -$5.7 million in Q3 2025.